FY2025 · ended Dec 31, 2025 · Revenue $815,371, -67.7% YoY · Filed Mar 13, 2026
Onconetix, Inc. (ONCO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $815,371 and a net loss of $14.0 million. As of Jun 30, 2026 it held $5.9 million in cash and investments and $36,734 in total debt.
Revenue (TTM)
$645,824
-51.3% vs year-ago TTM
Net income (TTM)
$-10.20M
+76.9% vs year-ago TTM
Operating cash flow (TTM)
$-10.31M
-88.3% vs year-ago TTM
Free cash flow
$-10.52M
+22.5% vs prior year
EPS (TTM)
$-6.77
+99.5% vs year-ago TTM
Dividend per share
$1.23
Shares outstanding
3.58M
-91.9% vs prior year
Net cash
$5.91M
as of Jun 30, 2026
Operating margin
-2525.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ONCO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cincinnati, OH
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1782107
- Former names
- Blue Water Biotech, Inc. (until Dec 18, 2023); Blue Water Vaccines Inc. (until Apr 20, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
|---|---|---|---|
| Revenue | $815,371 | $2.5M | $58,465 |
| Operating income | -$17.9M | -$56.5M | -$36.0M |
| Net income | -$14.0M | -$58.7M | — |
| Diluted EPS | -$16.56 | -$1,823.39 | -$87.45 |
| Operating cash flow | -$9.7M | -$10.5M | -$13.6M |
| Free cash flow | — | -$10.5M | -$13.6M |
| Total assets | $24.9M | $28.2M | $87.5M |
| Total liabilities | $9.2M | $18.6M | $21.9M |
| Stockholders' equity | $15.8M | $8.5M | $1.4M |
| Cash and investments | $5.2M | $646,500 | $4.6M |
| Total debt | $48,774 | $119,427 | $148,542 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Nov 6, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Oct 26, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Other events
|
Oct 23, 2026 | Oct 22, 2026 |
| ARS | Annual report to shareholders | Oct 16, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Sep 14, 2026 | Sep 11, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
All 398 Onconetix, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.